In a study, it was shown that early administration of inhaled budesonide reduced the chances of needing urgent medical care and reduced time to recovery after early COVID 19. 

Previous studies have shown that in COVID 19 patients, clinicians should be aware that there is no evidence to support the withdrawal of inhaled corticosteroids in patients treated with these drugs, and it may even be harmful in such patients. 

The study was an open-label, parallel-group, phase-2, randomized controlled trial of inhaled budesonide, compared with usual care, in adults within 7 days of the onset of mild COVID-19 symptoms. The results of the study showed that primary outcome (COVID 19 related urgent care visit, including emergency department assessment or hospitalization) occurred in ten (14%) of 70 participants in the usual care group and one (1%) of 69 participants in the budesonide group. Clinical recovery was 1 day shorter n the budesonide group compared with the usual care group in the budesonide group vs 8 days in the usual care group. Also, as needed antipyretic medication was needed for fewer proportion of days in the budesonide group compared with the usual care group. The study also reported that budesonide was safe, with only five (7%) participants reporting self-limiting adverse events.